Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
US11548941B2 · kind B2 · utility
0Cited by
134References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 19, 2019 |
| Grant date | Jan 10, 2023 |
| Priority date | — |
| Expiry date | Nov 19, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.